10-Year Lag in Survival Benefit After Breast/Colorectal Cancer Screening

Share this content:
10-Year Lag in Survival Benefit After Cancer Screening
10-Year Lag in Survival Benefit After Cancer Screening

(HealthDay News) -- Breast and colorectal cancer screening have, on average, a 10-year time lag to survival benefit, according to a meta-analysis published online Jan. 8 in BMJ.

Sei J. Lee, M.D., from the University of California in San Francisco, and colleagues conducted a meta-analysis using survival data from population-based, randomized, controlled trials comparing populations (aged 40 years and older) screened and not screened for breast or colorectal cancer (using mammography and fecal occult blood testing, respectively).

The researchers used five breast and four colorectal cancer screening trials to examine the estimated length of time needed after screening to observe a survival benefit. It took 3.0 years before one death from breast cancer was prevented for every 5,000 women screened and, on average, 10.7 years before one death from breast cancer was prevented for 1,000 women screened. It took 4.8 years before one death from colorectal cancer was prevented for 5,000 patients screened and, on average, 10.3 years before one death from colorectal cancer was prevented for 1,000 patients screened.

"Our results suggest that screening for breast and colorectal cancer is most appropriate for patients with a life expectancy greater than 10 years," the authors write.

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs